Table 1.
Characteristics of participants
| Characteristics | Controls (n = 11) | Vaccinated (n = 9) | Infected and vaccinated (n = 22) |
|---|---|---|---|
| Age (year), median (IQR) | 21 (19–24) | 25 (23–41) | 35 (20–57) |
| Female, n (%) | 7 (64) | 5 (56) | 13 (59) |
| Infection history | |||
| Time since symptomatic infection in days, median (min–max) | n/a | n/a | 266 (37–570) |
| NIH clinical score, median (IQR) | n/a | n/a | 3 (1-4) |
| Infection in relation to vaccination | n/a | n/a |
Primary infection = 13 Breakthrough infection = 4 Unknown = 5 |
| Vaccination history | |||
| Vaccine doses | n/a |
2 doses, n = 7 3 doses, n = 2 |
2 doses, n = 15 3 doses, n = 7 |
| Vaccine type | n/a |
BNT162b2, n = 6 ChAdOx1_S, n = 2 ChAdOx1_S/ BNT162b2, n = 1 |
BNT162b2, n = 15 Moderna, n = 1 ChAdOx1_S, n = 5 ChAdOx1_S/ BNT162b2, n = 1 |
| Time since 2nd or 3rd vaccine dose in days, median (min–max) | n/a | 130 (23–249) | 114 (23−392) |